L-DAB HBR

Research use only, not for human use.

L-DAB HBR is an inhibitor of GABA transaminase (IC50 > 500 μM).

L-DAB HBR is an inhibitor of GABA transaminase (IC50 > 500 μM).

The tumor cells are irreversibly and totally damaged by incubation with 10 mM L-2,4-Diaminobutyric acid for 24 h at 37°C. The cell-destructive effect by L-DABA is probably due to an osmotic lysis induced by the non-saturated intracellular accumulation of L-DABA. The harmful effect of L-DABA could be abolished by concomitant incubation with L-alanine and L-methionine. Kinetic studies indicates that L-DABA is a non-linear, non-competitive inhibitor of GABA transaminase activity. The L-DABA-induced elevation of GABA levels parallels the inhibition of GABA transaminase activity. L-2,4-Diaminobutyric acid, an amino acid analogue, produceS a cytolytic effect with a human glioma cell line, SKMG-1, and normal human fibroblasts. The concentrations of L-DABA necessary to reduce the cell count to 50% of control following a 24-h incubation at 37°C are 12.5 mM for the human fibroblasts and 20 mM for the glioma cell line.

Treatment with L-DABA results in 43.4% reduction of tumor growth. L-DABA is a more effective inhibitor of GABA transaminase in vivo than in vitro.

L-24-Diaminobutyric acid

Others

Other Targets

GABA|Human Endogenous Metabolite

——

——

1758-80-1

118.13

C4H10N2O2

>98% (HPLC)

H2O:34 mg/mL (287.82 mM)

NCC[C@H](N)C(=O)O

——

(-20℃)

With Ice Pack

≥ 2 years